The AFFIRM-AHF trial showed that treatment with IV ferric carboxymaltose (FCM) in patients stabilized after acute HF and with concomitant iron deficiency reduced hospitalization due to HF.

The FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 for recommending use of the ARNI sacubitril/valsartan in treatment of patients with HFpEF.

In the AFFIRM-AHF trial, the effect of administration of IV ferric carboxymaltose at hospital discharge on hard outcomes was examined in patients stabilized after an acute HF episode and concomitant iron deficiency.

Findings of a study using real-world data from REGARDS showed that prevalence of polypharmacy, defined as ≥10 medications, is high in older patients hospitalized for HF.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.

AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

AHA 2020 The GALACTIC-HF trial showed that omecamtiv mecarbil reduced the primary outcome of HF hospitalization and CV death in patients with HFrEF.

AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.

Three experts in this field discuss in three separate videos: the comorbidity burden in HF patients, the effect of hyperkalemia on use of RAASi and the enabling of RAASi therapy with potassium binders.

High-risk HFrEF patients with worsening HF and NT-proBNP levels up to 8000 pg/ml had a reduced risk of CV death and HF hospitalization when treated with vericiguat compared to placebo.

Prof. Van der Meer gives an introduction to the symposium about comorbidities in HF with a specific focus on hyperkalemia, that was held during the virtual ESC 2020 congress.